EMP2 and non-small cell lung carcinoma: Since it is well recognized that aberrant activation of the MAPK pathway promotes cell proliferation, metastasis, and cell survival, we speculate that EMP2 might suppress NSCLC cell growth mainly by inhibiting the MAPK pathway.